ClinTec ceo receives Honorary Doctorate

For her contribution to life sciences industry

Dr Rabinder Buttar has been awarded a Doctorate of the University (DUniv) by the University of the West of Scotland.

This honorary doctorate was awarded in recognition of Dr Buttar’s contribution to the life sciences Industry over 20 years and for the foundation and development of ClinTec International.

Professor Seamus McDaid, principal and vice chancellor of the University of the West of Scotland, said: ‘We are delighted to award Dr Buttar with an Honorary Doctorate. As chief executive of ClinTec International, she is one of the country’s most important business leaders, making a hugely important contribution to the Scottish economy.’

At the graduation ceremony, which took place in Paisley, Dr Buttar said: ‘The University has created an exceptional pool of local and international graduates and I am honoured to come back here after 20 years and accept this degree. These graduates here today have successfully completed one chapter of their lives and as they open the next one their learning should never stop.

‘In the current challenging times, graduates should seek local as well as global opportunities, look to do something they feel passionate about, be even more determined than ever before to succeed and then further success will be in their hands. The University and its excellent staff have prepared them well for the challenges that lie ahead.

‘I feel honoured and privileged to join the Court and Senate today in recognising and celebrating in some of Scotland’s academic achievements.’

Dr Buttar has also been named as the Ernst & Young Entrepreneur of the Year for Scotland and the Institute of Directors’ Regional Director of the Year for the West of Scotland.

You may also like

Research & Development

ClinTec expands into China, Singapore and Thailand

Increases presence in emerging markets
Finance

Pharmaceutical firms win Queen’s Awards for Enterprise

Eight firms are lauded for their success in innovation and international trade
Manufacturing

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth
Finance

Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech
Finance

Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate reason for stopping the competitor's offer
Finance

Custom Pharmaceuticals launches new company to foster breakthrough drug development and strategic partnerships

Custom Pharmaceuticals Ltd has launched Centrix Pharma Solutions, a new company dedicated to accelerating drug product development through collaboration with biotech firms and academic research
Finance

Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion
Subscribe now